WO2003016275A1 - Antiviral agent - Google Patents
Antiviral agent Download PDFInfo
- Publication number
- WO2003016275A1 WO2003016275A1 PCT/JP2002/008108 JP0208108W WO03016275A1 WO 2003016275 A1 WO2003016275 A1 WO 2003016275A1 JP 0208108 W JP0208108 W JP 0208108W WO 03016275 A1 WO03016275 A1 WO 03016275A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ring
- formula
- antiviral agent
- compound
- integrase
- Prior art date
Links
- 239000003443 antiviral agent Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 102100034343 Integrase Human genes 0.000 abstract 1
- 108010061833 Integrases Proteins 0.000 abstract 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- -1 hydroxy, mercapto Chemical class 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 229940124524 integrase inhibitor Drugs 0.000 abstract 1
- 239000002850 integrase inhibitor Substances 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 239000011593 sulfur Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
- C07D207/38—2-Pyrrolones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/40—Radicals substituted by oxygen atoms
- C07D307/46—Doubly bound oxygen atoms, or two oxygen atoms singly bound to the same carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
- C07D311/24—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrane Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003521202A JP4338192B2 (ja) | 2001-08-10 | 2002-08-08 | 抗ウイルス剤 |
KR1020047002062A KR100977701B1 (ko) | 2001-08-10 | 2002-08-08 | 항바이러스제 |
ES02749384T ES2383262T3 (es) | 2001-08-10 | 2002-08-08 | Agente antiviral |
EP02749384A EP1422218B1 (en) | 2001-08-10 | 2002-08-08 | Antiviral agent |
AT02749384T ATE550320T1 (de) | 2001-08-10 | 2002-08-08 | Antivirales mittel |
US10/485,394 US20040229909A1 (en) | 2001-08-10 | 2002-08-08 | Antiviral agent |
CA2452769A CA2452769C (en) | 2001-08-10 | 2002-08-08 | Antiviral agent |
MXPA04000646A MXPA04000646A (es) | 2001-08-10 | 2002-08-08 | Agente antiviral. |
BR0211750-9A BR0211750A (pt) | 2001-08-10 | 2002-08-08 | Agente antiviral |
US14/603,979 US9572813B2 (en) | 2001-08-10 | 2015-01-23 | Antiviral agent |
US15/356,343 US20170066754A1 (en) | 2001-08-10 | 2016-11-18 | Antiviral agent |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001-245071 | 2001-08-10 | ||
JP2001245071 | 2001-08-10 | ||
JP2001370860 | 2001-12-05 | ||
JP2001-370860 | 2001-12-05 | ||
JP2002191483 | 2002-06-28 | ||
JP2002-191483 | 2002-06-28 |
Related Child Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/485,394 A-371-Of-International US20040229909A1 (en) | 2001-08-10 | 2002-08-08 | Antiviral agent |
US10485394 A-371-Of-International | 2002-08-08 | ||
US14/603,979 Continuation US9572813B2 (en) | 2001-08-10 | 2015-01-23 | Antiviral agent |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003016275A1 true WO2003016275A1 (en) | 2003-02-27 |
Family
ID=27347328
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2002/008108 WO2003016275A1 (en) | 2001-08-10 | 2002-08-08 | Antiviral agent |
Country Status (16)
Country | Link |
---|---|
US (3) | US20040229909A1 (ja) |
EP (4) | EP1422218B1 (ja) |
JP (3) | JP4338192B2 (ja) |
KR (2) | KR20100087209A (ja) |
CN (2) | CN100491349C (ja) |
AT (2) | ATE550320T1 (ja) |
BR (1) | BR0211750A (ja) |
CA (1) | CA2452769C (ja) |
CY (2) | CY20162200001T2 (ja) |
DE (2) | DE15187654T1 (ja) |
DK (2) | DK3042894T1 (ja) |
ES (3) | ES2587564T1 (ja) |
MX (1) | MXPA04000646A (ja) |
PT (1) | PT2266958T (ja) |
TW (1) | TWI327137B (ja) |
WO (1) | WO2003016275A1 (ja) |
Cited By (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004072063A1 (en) * | 2003-02-07 | 2004-08-26 | Vertex Pharmaceuticals Incorporated | Heteroaryl substituted pyrolls useful as inhibitors of protein kinases |
JP2004250693A (ja) * | 2003-01-29 | 2004-09-09 | Sanyo Chem Ind Ltd | ウレタン樹脂及びその粉体の製造方法 |
WO2005061490A1 (ja) | 2003-12-22 | 2005-07-07 | Shionogi & Co., Ltd. | Hivインテグラーゼ阻害活性を有するヒドロキシピリミジノン誘導体 |
WO2005087766A1 (en) | 2004-03-09 | 2005-09-22 | Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa | Hiv integrase inhibitors |
WO2006030807A1 (ja) * | 2004-09-15 | 2006-03-23 | Shionogi & Co., Ltd. | Hivインテグラーゼ阻害活性を有するカルバモイルピリドン誘導体 |
US7037908B2 (en) | 2003-04-24 | 2006-05-02 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
US7109186B2 (en) | 2002-07-09 | 2006-09-19 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
JP2006342115A (ja) * | 2005-06-10 | 2006-12-21 | Shionogi & Co Ltd | Hivインテグラーゼ阻害活性を有する多環性化合物 |
US7211572B2 (en) | 2003-08-13 | 2007-05-01 | Japan Tobacco Inc. | Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor |
US7414045B2 (en) | 2002-12-27 | 2008-08-19 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Substituted pyrimido[1,2-a]azepines useful as HIV integrase inhibitors |
US7585868B2 (en) | 2006-04-04 | 2009-09-08 | The Regents Of The University Of California | Substituted pyrazolo[3,4-D]pyrimidines as kinase antagonists |
US8129385B2 (en) | 2005-04-28 | 2012-03-06 | Shionogi & Co., Ltd. | Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness |
US8476282B2 (en) | 2008-11-03 | 2013-07-02 | Intellikine Llc | Benzoxazole kinase inhibitors and methods of use |
US8569323B2 (en) | 2009-07-15 | 2013-10-29 | Intellikine, Llc | Substituted isoquinolin-1(2H)-one compounds, compositions, and methods thereof |
US8604032B2 (en) | 2010-05-21 | 2013-12-10 | Infinity Pharmaceuticals, Inc. | Chemical compounds, compositions and methods for kinase modulation |
US8637542B2 (en) | 2008-03-14 | 2014-01-28 | Intellikine, Inc. | Kinase inhibitors and methods of use |
US8697709B2 (en) | 2008-10-16 | 2014-04-15 | The Regents Of The University Of California | Fused ring heteroaryl kinase inhibitors |
US8703778B2 (en) | 2008-09-26 | 2014-04-22 | Intellikine Llc | Heterocyclic kinase inhibitors |
US8703777B2 (en) | 2008-01-04 | 2014-04-22 | Intellikine Llc | Certain chemical entities, compositions and methods |
US8785454B2 (en) | 2009-05-07 | 2014-07-22 | Intellikine Llc | Heterocyclic compounds and uses thereof |
US8785470B2 (en) | 2011-08-29 | 2014-07-22 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US8809349B2 (en) | 2011-01-10 | 2014-08-19 | Infinity Pharmaceuticals, Inc. | Processes for preparing isoquinolinones and solid forms of isoquinolinones |
US8828998B2 (en) | 2012-06-25 | 2014-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
US8835449B2 (en) | 2011-11-11 | 2014-09-16 | Pfizer Inc. | 2-thiopyrimidinones |
US8901133B2 (en) | 2010-11-10 | 2014-12-02 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US8969363B2 (en) | 2011-07-19 | 2015-03-03 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US8980899B2 (en) | 2009-10-16 | 2015-03-17 | The Regents Of The University Of California | Methods of inhibiting Ire1 |
US8993580B2 (en) | 2008-03-14 | 2015-03-31 | Intellikine Llc | Benzothiazole kinase inhibitors and methods of use |
US9056877B2 (en) | 2011-07-19 | 2015-06-16 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US9096611B2 (en) | 2008-07-08 | 2015-08-04 | Intellikine Llc | Kinase inhibitors and methods of use |
US9200009B2 (en) | 2011-10-12 | 2015-12-01 | Shionogi & Co., Ltd. | Polycyclic pyridone derivative having integrase inhibitory activity |
US9216995B2 (en) | 2010-04-12 | 2015-12-22 | Shionogi & Co., Ltd. | Pyridone derivative having integrase inhibitory activity |
WO2016021539A1 (ja) * | 2014-08-06 | 2016-02-11 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ピリミジン-1-オール化合物の製造方法及びその中間体 |
US9295673B2 (en) | 2011-02-23 | 2016-03-29 | Intellikine Llc | Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof |
US9321772B2 (en) | 2011-09-02 | 2016-04-26 | The Regents Of The University Of California | Substituted pyrazolo[3,4-D]pyrimidines and uses thereof |
US9359365B2 (en) | 2013-10-04 | 2016-06-07 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US9359349B2 (en) | 2007-10-04 | 2016-06-07 | Intellikine Llc | Substituted quinazolines as kinase inhibitors |
US9481667B2 (en) | 2013-03-15 | 2016-11-01 | Infinity Pharmaceuticals, Inc. | Salts and solid forms of isoquinolinones and composition comprising and methods of using the same |
US9512125B2 (en) | 2004-11-19 | 2016-12-06 | The Regents Of The University Of California | Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents |
US9572813B2 (en) | 2001-08-10 | 2017-02-21 | Shionogi & Co., Ltd. | Antiviral agent |
US9629843B2 (en) | 2008-07-08 | 2017-04-25 | The Regents Of The University Of California | MTOR modulators and uses thereof |
CN106810458A (zh) * | 2016-12-31 | 2017-06-09 | 武汉工程大学 | 一种拆分dl‑2‑氨基丙醇制备l‑2‑氨基丙醇的方法 |
US9708348B2 (en) | 2014-10-03 | 2017-07-18 | Infinity Pharmaceuticals, Inc. | Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof |
US9751888B2 (en) | 2013-10-04 | 2017-09-05 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US9771332B2 (en) | 2015-05-05 | 2017-09-26 | Pfizer Inc. | 2-thiopyrimidinones |
US9775844B2 (en) | 2014-03-19 | 2017-10-03 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
CN108658784A (zh) * | 2018-04-26 | 2018-10-16 | 联化科技股份有限公司 | (r)-1-(4-甲基苯基)乙胺的合成方法 |
US10131668B2 (en) | 2012-09-26 | 2018-11-20 | The Regents Of The University Of California | Substituted imidazo[1,5-a]pYRAZINES for modulation of IRE1 |
US10160761B2 (en) | 2015-09-14 | 2018-12-25 | Infinity Pharmaceuticals, Inc. | Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same |
WO2019054427A1 (ja) | 2017-09-14 | 2019-03-21 | 第一三共株式会社 | 環状構造を有する化合物 |
JP2019512485A (ja) * | 2016-03-08 | 2019-05-16 | ノバルティス アーゲー | オルトミクソウイルス感染の処置に有用な三環式化合物 |
WO2020083662A1 (en) | 2018-10-23 | 2020-04-30 | Basf Se | Tricyclic pesticidal compounds |
US10759806B2 (en) | 2016-03-17 | 2020-09-01 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors |
EP3757105A2 (en) | 2014-08-22 | 2020-12-30 | Shionogi & Co., Ltd | Polycyclic pyridone derivative having integrase inhibitory activity |
US10919914B2 (en) | 2016-06-08 | 2021-02-16 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US11098051B2 (en) | 2016-08-29 | 2021-08-24 | Novartis Ag | Fused tricyclic pyridazinone compounds useful to treat orthomyxovirus infections |
US11110096B2 (en) | 2014-04-16 | 2021-09-07 | Infinity Pharmaceuticals, Inc. | Combination therapies |
US11147818B2 (en) | 2016-06-24 | 2021-10-19 | Infinity Pharmaceuticals, Inc. | Combination therapies |
WO2021209265A1 (en) | 2020-04-14 | 2021-10-21 | Basf Se | Tricyclic pesticidal compounds |
US11629149B2 (en) | 2018-02-28 | 2023-04-18 | Novartis Ag | 10-(di(phenyl)methyl)-4-hydroxy-8,9,9A,10-tetrahydro-7H-pyrrolo[1′,2′:4,5]pyrazino[1,2-b]pyridazine-3,5-dione derivatives and related compounds as inhibitors of the orthomyxovirus replication for treating influenza |
Families Citing this family (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1441734T3 (da) | 2001-10-26 | 2007-06-11 | Angeletti P Ist Richerche Bio | Dihydroxypyrimidin-carboxamid-inhibitorer a HIV-integrase |
IL161337A0 (en) | 2001-10-26 | 2004-09-27 | Angeletti P Ist Richerche Bio | N-substituted hydroxypyrimidinone carboxamide inhibitors of hiv integrase |
US7135467B2 (en) | 2003-01-13 | 2006-11-14 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
US20050014753A1 (en) * | 2003-04-04 | 2005-01-20 | Irm Llc | Novel compounds and compositions as protein kinase inhibitors |
CN101014571A (zh) * | 2004-01-30 | 2007-08-08 | 默克公司 | 用作hiv整合酶抑制剂的n-苄基-3,4-二羟基吡啶-2-羧酰胺类和n-苄基-2,3-二羟基吡啶-4-羧酰胺类化合物 |
US7820680B2 (en) | 2004-03-09 | 2010-10-26 | Merck & Co., Inc. | HIV integrase inhibitors |
EA200601654A1 (ru) * | 2004-03-09 | 2007-02-27 | Мерк Энд Ко., Инк. | Ингибиторы интегразы вич |
US7619086B2 (en) * | 2004-03-09 | 2009-11-17 | Merck & Co., Inc. | HIV integrase inhibitors |
US7538112B2 (en) * | 2004-05-07 | 2009-05-26 | Merck & Co., Inc. | HIV integrase inhibitors |
US7115601B2 (en) * | 2004-05-18 | 2006-10-03 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
JP2008502741A (ja) * | 2004-06-09 | 2008-01-31 | メルク エンド カムパニー インコーポレーテッド | Hivインテグラーゼ阻害薬 |
JP5317257B2 (ja) * | 2005-02-21 | 2013-10-16 | 塩野義製薬株式会社 | Hivインテグラーゼ阻害活性を有する2環性カルバモイルピリドン誘導体 |
CN101146811B (zh) | 2005-03-31 | 2012-01-11 | P.安杰莱蒂分子生物学研究所 | Hiv整合酶抑制剂 |
US7741315B2 (en) * | 2005-05-10 | 2010-06-22 | Merck Sharp & Dohme Corp. | HIV integrase inhibitors |
US7939537B2 (en) * | 2005-10-04 | 2011-05-10 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | HIV integrase inhibitors |
KR20080064182A (ko) | 2005-10-27 | 2008-07-08 | 시오노기세야쿠 가부시키가이샤 | Hiv 인테그라아제 억제활성을 가지는 다환성카르바모일피리돈 유도체 |
WO2007054105A2 (en) * | 2005-11-14 | 2007-05-18 | H. Lundbeck A/S | Method for the preparation of escitalopram |
US20100056516A1 (en) * | 2006-07-17 | 2010-03-04 | Williams Peter D | 1-hydroxy naphthyridine compounds as anti-hiv agents |
US20110130397A1 (en) * | 2006-09-22 | 2011-06-02 | Soongyu Choi | Pyrrolinone compounds as inhibitors of bacterial peptidyl trna hydrolase and uses thereof |
AU2007313293A1 (en) * | 2006-10-18 | 2008-04-24 | Merck & Co., Inc. | HIV integrase inhibitors |
EP2095819A1 (en) * | 2008-02-28 | 2009-09-02 | Maastricht University | N-benzyl imidazole derivatives and their use as aldosterone synthase inhibitors |
DE102008028905A1 (de) | 2008-06-18 | 2009-12-24 | Merck Patent Gmbh | 3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyridazinderivate |
WO2010000030A1 (en) | 2008-07-02 | 2010-01-07 | Avexa Limited | Thiazopyrimidinones and uses thereof |
CA2729663A1 (en) | 2008-07-02 | 2010-01-07 | Avexa Limited | Compounds having antiviral properties |
CA2729656A1 (en) * | 2008-07-02 | 2010-01-07 | Avexa Limited | Imidazopyrimidinones and uses thereof |
US20100041653A1 (en) * | 2008-08-15 | 2010-02-18 | Burnham Institute For Medical Research | Composition and methods for the design and development of metallo-enzyme inhibitors |
BRPI0920605A8 (pt) * | 2008-10-06 | 2016-04-26 | Merck Sharp & Dohme | Composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, método para o tratamento ou profilaxia de infecção pelo hiv ou para o tratamento, profilaxia, ou retardo no início ou progressão da aids em um paciente em necessidade deste. |
JP2012532849A (ja) * | 2009-07-10 | 2012-12-20 | ビバリス | C型肝炎ns5bポリメラーゼの阻害剤としての1−(6員アゾ複素環式)−ピロリン−2−オン化合物、その医薬組成物、およびそれらの治療上の使用 |
CN101967209B (zh) * | 2010-10-20 | 2012-11-07 | 南京大学 | 一种n-乙酰基乙二胺螯合树脂及其制备方法 |
GB201020076D0 (en) * | 2010-11-26 | 2011-01-12 | Liverpool School Tropical Medicine | Antimalarial compounds |
WO2013048982A1 (en) | 2011-09-27 | 2013-04-04 | Bristol-Myers Squibb Company | Pyrrolinone carboxamide compounds useful as endothelial lipase inhibitors |
EP2760828B1 (en) | 2011-09-27 | 2015-10-21 | Bristol-Myers Squibb Company | Pyrrolinone carboxamide compounds useful as endothelial lipase inhibitors |
WO2013048928A1 (en) | 2011-09-27 | 2013-04-04 | Bristol-Myers Squibb Company | Pyrrolinone carboxamide compounds useful as endothelial lipase inhibitors |
JP6183053B2 (ja) * | 2012-08-22 | 2017-08-23 | 宇部興産株式会社 | テトラヒドロピラニルピリミジン化合物の製造方法 |
US9714243B2 (en) | 2012-12-17 | 2017-07-25 | Merck Sharp & Dohme Corp. | 4-pyridinonetriazine derivatives as HIV integrase inhibitors |
PT3608325T (pt) | 2012-12-21 | 2022-10-17 | Gilead Sciences Inc | Compostos carbamoílpiridona policíclicos e sua utilização farmacêutica |
CN103172581A (zh) * | 2013-04-07 | 2013-06-26 | 杨国成 | 一种5-氨基-3-巯基-1,2,4-三氮唑晶体及其制备方法 |
EP2986291B1 (en) | 2013-04-16 | 2020-05-27 | Merck Sharp & Dohme Corp. | 4-pyridone derivative compounds and uses thereof as hiv integrase inhibitors |
GB201308217D0 (en) | 2013-05-08 | 2013-06-12 | Ucl Business Plc | Compounds and their use in therapy |
CN104148018B (zh) * | 2013-05-14 | 2018-04-20 | 上海亨臻实业有限公司 | 抗体亲和纯化材料及其用途 |
ME02977B (me) | 2013-05-17 | 2018-10-20 | Merck Sharp & Dohme | Fuzionisana triciklicna heterociklicna jedinjenja као inhibiтori hiv integraze |
US9951079B2 (en) | 2013-06-13 | 2018-04-24 | Merck Sharp & Dohme Corp. | Fused tricyclic heterocyclic compounds as HIV integrase inhibitors |
NO2865735T3 (ja) | 2013-07-12 | 2018-07-21 | ||
PT3019503T (pt) | 2013-07-12 | 2017-11-27 | Gilead Sciences Inc | Compostos carbamoílpiridona- policíclicos e seu uso para o tratamento de infecções por hiv |
WO2015048363A1 (en) | 2013-09-27 | 2015-04-02 | Merck Sharp & Dohme Corp. | Substituted quinolizine derivatives useful as hiv integrase inhibitors |
WO2015117094A1 (en) * | 2014-02-03 | 2015-08-06 | American Life Science Pharmaceuticals, Inc. | Compositions and methods for synthesizing (2s,3s)-trans-epoxysuccinyl-l-leucyl-amido-3-methylbutane ethyl ester |
TWI677489B (zh) | 2014-06-20 | 2019-11-21 | 美商基利科學股份有限公司 | 多環型胺甲醯基吡啶酮化合物之合成 |
NO2717902T3 (ja) | 2014-06-20 | 2018-06-23 | ||
TW201613936A (en) | 2014-06-20 | 2016-04-16 | Gilead Sciences Inc | Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide |
TWI695003B (zh) | 2014-12-23 | 2020-06-01 | 美商基利科學股份有限公司 | 多環胺甲醯基吡啶酮化合物及其醫藥用途 |
PL3277691T3 (pl) | 2015-04-02 | 2019-07-31 | Gilead Sciences, Inc. | Policykliczne związki karbamoilopirydonowe i ich zastosowanie farmaceutyczne |
WO2016187788A1 (en) | 2015-05-25 | 2016-12-01 | Merck Sharp & Dohme Corp. | Fused tricyclic heterocyclic compounds useful for treating hiv infection |
CN105237406A (zh) * | 2015-10-14 | 2016-01-13 | 湖南华腾制药有限公司 | (r)-(-)-1-甲基-3-苯丙胺的合成方法 |
US10611747B2 (en) | 2015-11-09 | 2020-04-07 | Forge Therapeutics, Inc. | Pyrone based compounds for treating bacterial infections |
EP3374350B1 (en) | 2015-11-09 | 2022-01-05 | Forge Therapeutics, Inc. | Hydroxypyridinone and hydroxypyrimidinone based compounds for treating bacterial infections |
WO2017087257A1 (en) | 2015-11-17 | 2017-05-26 | Merck Sharp & Dohme Corp. | Amido-substituted pyridotriazine derivatives useful as hiv integrase inhibitors |
EP3389380B1 (en) | 2015-12-15 | 2021-07-21 | Merck Sharp & Dohme Corp. | Spirocyclic quinolizine derivatives useful as hiv integrase inhibitors |
WO2017113288A1 (en) | 2015-12-31 | 2017-07-06 | Merck Sharp & Dohme Corp. | Fused tricyclic heterocyclic compounds as hiv integrase inhibitors |
WO2017190050A1 (en) * | 2016-04-28 | 2017-11-02 | Cornell University | Inhibitors of soluble adenylyl cyclase |
CN107773562B (zh) * | 2016-08-25 | 2020-04-07 | 清华大学 | 化合物在抗登革和寨卡病毒感染中的应用 |
JOP20190130A1 (ar) | 2016-12-02 | 2019-06-02 | Merck Sharp & Dohme | مركبات حلقية غير متجانسة رباعية الحلقات مفيدة كمثبطات إنزيم مدمج لفيروس نقص المناعة البشرية (hiv) |
RU2749043C2 (ru) | 2016-12-02 | 2021-06-03 | Мерк Шарп И Доум Корп. | Трициклические гетероциклические соединения, полезные в качестве ингибиторов интегразы вич |
EP3573984A4 (en) | 2017-01-26 | 2020-07-29 | Merck Sharp & Dohme Corp. | USEFUL SUBSTITUTE QUINOLIZINE DERIVATIVES AS HIV INTEGRASE INHIBITORS |
CN110431224A (zh) * | 2017-03-13 | 2019-11-08 | 帝斯曼知识产权资产管理有限公司 | 锌双核簇转录调控因子缺陷型菌株 |
WO2018166855A1 (en) | 2017-03-16 | 2018-09-20 | Basf Se | Heterobicyclic substituted dihydroisoxazoles |
US11021471B2 (en) * | 2017-05-10 | 2021-06-01 | Forge Therapeutics, Inc. | Antibacterial compounds |
JP7495395B2 (ja) | 2018-09-20 | 2024-06-04 | ブラックスミス メディシンズ,インク. | 抗菌性化合物 |
WO2020132820A1 (zh) * | 2018-12-24 | 2020-07-02 | 广东莱佛士制药技术有限公司 | 一种3-(苄氧基)-4-氧代-4h-吡喃-2-羧酸的合成方法 |
RU2717101C1 (ru) | 2019-06-03 | 2020-03-18 | Андрей Александрович Иващенко | Анелированные 9-гидрокси-1,8-диоксо-1,3,4,8-тетрагидро-2Н-пиридо[1,2-a]пиразин-7-карбоксамиды - ингибиторы интегразы ВИЧ, способы их получения и применения |
US20200398978A1 (en) | 2019-06-20 | 2020-12-24 | Bell Helicopter Textron Inc. | Low-drag rotor blade extension |
CN110563943A (zh) * | 2019-09-09 | 2019-12-13 | 中国科学院长春应用化学研究所 | 一种生物基聚合物及其制备方法 |
WO2021195260A1 (en) | 2020-03-25 | 2021-09-30 | Forge Therapeutics, Inc. | Lpxc inhibitor and methods of making |
KR20230074174A (ko) | 2020-09-21 | 2023-05-26 | 란도스 바이오파마, 인크. | Nlrx1 리간드 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992002523A1 (en) | 1990-08-02 | 1992-02-20 | Sankei Pharmaceutical Company Limited | Novel cephalosporin compound |
JPH06100445A (ja) * | 1992-07-06 | 1994-04-12 | Banyu Pharmaceut Co Ltd | 抗腫瘍剤 |
WO2000039086A1 (fr) * | 1998-12-25 | 2000-07-06 | Shionogi & Co., Ltd. | Composes heterocycliques aromatiques possedant des activites inhibitrices de l'integrase du vih |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3244725A (en) | 1964-09-21 | 1966-04-05 | Taub William | 4, 5-diacyl-3-hydroxy-3-pyrrolin-2-ones |
US4298743A (en) * | 1979-09-11 | 1981-11-03 | Merck & Co., Inc. | 4-(Substituted phenyl thiazolyl)-3-hydroxy-3-pyrroline-2,5-diones |
DE3820176A1 (de) | 1987-12-18 | 1989-06-29 | Bayer Ag | Verfahren zur herstellung von phosphorsaeurederivaten und zwischenprodukten |
WO1992006954A2 (en) | 1990-10-15 | 1992-04-30 | Pfizer Inc. | Pyrrolidine dione derivatives |
JPH06100405A (ja) * | 1992-08-07 | 1994-04-12 | Yoshitomi Pharmaceut Ind Ltd | 水中防汚剤 |
WO1998011876A1 (de) | 1996-09-18 | 1998-03-26 | Marigen S.A. | Bioflavonol-glykosid-perester und ihre aufarbeitung zu pharmakologisch wirksamen konzentraten und ultramikroemulsionen |
CA2326166A1 (en) | 1998-03-26 | 1999-10-07 | Shionogi & Co., Ltd. | Indole derivatives with antiviral activity |
EP1082121A4 (en) | 1998-06-03 | 2003-02-05 | Merck & Co Inc | INTEGRASE HIV INHIBITORS |
EP1083897A4 (en) | 1998-06-03 | 2003-01-02 | Merck & Co Inc | HIV INTEGRASE INHIBITORS |
JP2002517390A (ja) | 1998-06-03 | 2002-06-18 | メルク エンド カムパニー インコーポレーテッド | Hivインテグラーゼ阻害薬 |
US6610692B1 (en) | 1998-10-30 | 2003-08-26 | Merck & Co., Inc. | Thrombin inhibitors |
GB2345058A (en) | 1998-12-01 | 2000-06-28 | Cerebrus Pharm Ltd | Hydroxypyridone compounds useful in the treatment of oxidative damage to the central nervous system |
AU5880600A (en) | 1999-06-25 | 2001-01-31 | Merck & Co., Inc. | 1-(aromatic- or heteroaromatic-substituted)-3-(heteroaromatic substituted)-1,3-propanediones and uses thereof |
AU6731100A (en) | 1999-09-02 | 2001-04-10 | Shionogi & Co., Ltd. | Integrase inhibitors containing aromatic heterocycle derivatives |
JP2001270884A (ja) | 2000-03-23 | 2001-10-02 | Mitsubishi-Tokyo Pharmaceuticals Inc | ピリミドン誘導体 |
US20040039060A1 (en) * | 2000-06-14 | 2004-02-26 | Ryuichi Kiyama | Inhibitor for enzyme having two divalent metal ions as active centers |
WO2002036734A2 (en) | 2000-10-12 | 2002-05-10 | Merck & Co., Inc. | Aza-and polyaza-naphthalenyl ketones useful as hiv integrase inhibitors |
ATE430745T1 (de) | 2000-10-12 | 2009-05-15 | Merck & Co Inc | Aza- und polyaza naphthalenyl karboxamide als inhibitoren der hiv-integrase |
AU1532802A (en) | 2000-10-12 | 2002-04-22 | Merck & Co Inc | Aza- and polyaza-naphthalenyl-carboxamides useful as hiv integrase inhibitors |
KR20030078958A (ko) | 2001-03-01 | 2003-10-08 | 시오노기세이야쿠가부시키가이샤 | Hiv 인테그라제 저해 활성을 갖는 질소 함유의헤테로아릴 화합물 |
JP4176477B2 (ja) | 2001-03-01 | 2008-11-05 | 塩野義製薬株式会社 | Hivインテグラーゼ阻害活性を有する含窒素芳香族複素環誘導体 |
ES2587564T1 (es) | 2001-08-10 | 2016-10-25 | Shionogi & Co., Ltd. | Agente antiviral |
WO2003030897A1 (en) * | 2001-10-03 | 2003-04-17 | Ucb, S.A. | Pyrrolidinone derivatives |
IL161337A0 (en) | 2001-10-26 | 2004-09-27 | Angeletti P Ist Richerche Bio | N-substituted hydroxypyrimidinone carboxamide inhibitors of hiv integrase |
DK1441734T3 (da) | 2001-10-26 | 2007-06-11 | Angeletti P Ist Richerche Bio | Dihydroxypyrimidin-carboxamid-inhibitorer a HIV-integrase |
WO2004004657A2 (en) | 2002-07-09 | 2004-01-15 | Bristol-Myers Squibb Company | Hiv integrase inhibitors |
TW200526635A (en) * | 2003-12-22 | 2005-08-16 | Shionogi & Co | Hydroxypyrimidinone derivative having HIV integrase inhibitory activity |
CN101014571A (zh) | 2004-01-30 | 2007-08-08 | 默克公司 | 用作hiv整合酶抑制剂的n-苄基-3,4-二羟基吡啶-2-羧酰胺类和n-苄基-2,3-二羟基吡啶-4-羧酰胺类化合物 |
US9328075B2 (en) | 2011-05-05 | 2016-05-03 | St. Jude Children's Research Hospital | Pyrimidinone compounds and methods for treating influenza |
-
2002
- 2002-08-08 ES ES15187654.7T patent/ES2587564T1/es active Pending
- 2002-08-08 ES ES10178132.6T patent/ES2572030T3/es not_active Expired - Lifetime
- 2002-08-08 EP EP02749384A patent/EP1422218B1/en not_active Revoked
- 2002-08-08 CN CNB028198697A patent/CN100491349C/zh not_active Expired - Fee Related
- 2002-08-08 DE DE15187654.7T patent/DE15187654T1/de active Pending
- 2002-08-08 CN CN2009101282803A patent/CN101513402B/zh not_active Expired - Fee Related
- 2002-08-08 EP EP09177978A patent/EP2181985B1/en not_active Expired - Lifetime
- 2002-08-08 KR KR1020107012655A patent/KR20100087209A/ko not_active Application Discontinuation
- 2002-08-08 EP EP10178132.6A patent/EP2266958B1/en not_active Revoked
- 2002-08-08 AT AT02749384T patent/ATE550320T1/de active
- 2002-08-08 MX MXPA04000646A patent/MXPA04000646A/es active IP Right Grant
- 2002-08-08 US US10/485,394 patent/US20040229909A1/en not_active Abandoned
- 2002-08-08 PT PT101781326T patent/PT2266958T/pt unknown
- 2002-08-08 DK DK15187654.7T patent/DK3042894T1/da unknown
- 2002-08-08 KR KR1020047002062A patent/KR100977701B1/ko active IP Right Grant
- 2002-08-08 ES ES02749384T patent/ES2383262T3/es not_active Expired - Lifetime
- 2002-08-08 JP JP2003521202A patent/JP4338192B2/ja not_active Expired - Fee Related
- 2002-08-08 WO PCT/JP2002/008108 patent/WO2003016275A1/ja active Application Filing
- 2002-08-08 DK DK10178132.6T patent/DK2266958T1/da unknown
- 2002-08-08 DE DE10178132.6T patent/DE10178132T1/de active Pending
- 2002-08-08 BR BR0211750-9A patent/BR0211750A/pt not_active Application Discontinuation
- 2002-08-08 AT AT09177978T patent/ATE530520T1/de not_active IP Right Cessation
- 2002-08-08 CA CA2452769A patent/CA2452769C/en not_active Expired - Fee Related
- 2002-08-08 EP EP15187654.7A patent/EP3042894A1/en not_active Withdrawn
- 2002-08-09 TW TW091117986A patent/TWI327137B/zh not_active IP Right Cessation
-
2009
- 2009-03-11 JP JP2009057635A patent/JP5207392B2/ja not_active Expired - Lifetime
-
2012
- 2012-08-09 JP JP2012176768A patent/JP2012236852A/ja active Pending
-
2015
- 2015-01-23 US US14/603,979 patent/US9572813B2/en not_active Expired - Fee Related
-
2016
- 2016-05-10 CY CY20162200001T patent/CY20162200001T2/el unknown
- 2016-11-18 US US15/356,343 patent/US20170066754A1/en not_active Abandoned
- 2016-11-25 CY CY20162200002T patent/CY20162200002T2/el unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992002523A1 (en) | 1990-08-02 | 1992-02-20 | Sankei Pharmaceutical Company Limited | Novel cephalosporin compound |
JPH06100445A (ja) * | 1992-07-06 | 1994-04-12 | Banyu Pharmaceut Co Ltd | 抗腫瘍剤 |
WO2000039086A1 (fr) * | 1998-12-25 | 2000-07-06 | Shionogi & Co., Ltd. | Composes heterocycliques aromatiques possedant des activites inhibitrices de l'integrase du vih |
Non-Patent Citations (11)
Title |
---|
ANDREICHIKOV YU. S. ET AL.: "Five-membered-ring 2,3-dioxoheterocycles. XIV. Synthesis of 1,4-disubstituted 5-aryltetrahydropyrrole-2,3-diones by reaction of diethoxalylacetone with azomethines", ZH. ORG. KHIM., vol. 25, no. 12, 1989, pages 2494 - 2500, XP002957388 * |
BETAIL G. ET AL.: "Induction of antinuclear antibodies. Study of new molecules with a hydrazine structure or their analogs in mice", ANN. PHARM. FR., vol. 36, no. 7-8, 1978, pages 317 - 322, XP002957391 * |
ELBEN ULRICH, VOEGTLE FRITZ: "Cryptomycins - crown ether analogs of the actinomycins", J. CHEM. RES. (S), no. 9, 1978, pages 316 - 317, XP002957390 * |
J. ORG. CHEM., vol. 33, 1968, pages 2051 |
ORG. PREP. PROCED. INT., vol. 29, 1997, pages 330 - 335 |
PHAM HUU CHANH ET AL.: "Pharmacological aspects of pyrazoline derivatives from 2-hydroxybutenolides", ARZNEIM.-FORSCH., vol. 26, no. 11, 1976, pages 2050 - 2052, XP002957387 * |
See also references of EP1422218A4 |
SILHANKOVA ALEXANDRA ET AL.: "Studies in the pyridine series. part LVIII. Condensation reactions of 2,4- and 2,6-dimethylpyridines and their 1-oxides", COLLECT. CZECH. CHEM. COMMUN., vol. 54, no. 6, 1989, pages 1687 - 1704, XP002957386 * |
SKLYAROVA I.V. ET AL.: "Synthesis of actinomycin analogs. XVII. Actinomycin amides containing a benzimidazole fragment", ZH. ORG. KHIM., vol. 25, no. 1, 1989, pages 186 - 189, XP002957389 * |
TETRAHEDRON, vol. 53, no. 15, 1997, pages 5617 |
TETRAHEDRON, vol. 54, 1998, pages 12745 - 12774 |
Cited By (135)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9572813B2 (en) | 2001-08-10 | 2017-02-21 | Shionogi & Co., Ltd. | Antiviral agent |
US7109186B2 (en) | 2002-07-09 | 2006-09-19 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
US7414045B2 (en) | 2002-12-27 | 2008-08-19 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Substituted pyrimido[1,2-a]azepines useful as HIV integrase inhibitors |
US7968553B2 (en) | 2002-12-27 | 2011-06-28 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Tetrahydro-4H-pyrido[1,2-a] pyrimidines useful as HIV integrase inhibitors |
JP4607469B2 (ja) * | 2003-01-29 | 2011-01-05 | 三洋化成工業株式会社 | ウレタン樹脂及びその粉体の製造方法 |
JP2004250693A (ja) * | 2003-01-29 | 2004-09-09 | Sanyo Chem Ind Ltd | ウレタン樹脂及びその粉体の製造方法 |
US7407962B2 (en) | 2003-02-07 | 2008-08-05 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds useful as inhibitors or protein kinases |
JP2006518381A (ja) * | 2003-02-07 | 2006-08-10 | バーテックス ファーマシューティカルズ インコーポレイテッド | プロテインキナーゼのインヒビターとして有用なヘテロアリール置換ピロール |
WO2004072063A1 (en) * | 2003-02-07 | 2004-08-26 | Vertex Pharmaceuticals Incorporated | Heteroaryl substituted pyrolls useful as inhibitors of protein kinases |
US7037908B2 (en) | 2003-04-24 | 2006-05-02 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
US7211572B2 (en) | 2003-08-13 | 2007-05-01 | Japan Tobacco Inc. | Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor |
EP2042502A1 (en) | 2003-08-13 | 2009-04-01 | Japan Tobacco Inc. | Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor |
JP4798608B2 (ja) * | 2003-12-22 | 2011-10-19 | 塩野義製薬株式会社 | Hivインテグラーゼ阻害活性を有するヒドロキシピリミジノン誘導体 |
US7745453B2 (en) | 2003-12-22 | 2010-06-29 | Shionogi & Co., Ltd. | Hydroxypyrimidinone derivatives having inhibitory activity against HIV integrase |
WO2005061490A1 (ja) | 2003-12-22 | 2005-07-07 | Shionogi & Co., Ltd. | Hivインテグラーゼ阻害活性を有するヒドロキシピリミジノン誘導体 |
WO2005087766A1 (en) | 2004-03-09 | 2005-09-22 | Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa | Hiv integrase inhibitors |
JPWO2006030807A1 (ja) * | 2004-09-15 | 2008-05-15 | 塩野義製薬株式会社 | Hivインテグラーゼ阻害活性を有するカルバモイルピリドン誘導体 |
US7550463B2 (en) | 2004-09-15 | 2009-06-23 | Shionogi & Co., Ltd. | Carbamoylpyridone derivatives having inhibitory activity against HIV integrase |
JP4953297B2 (ja) * | 2004-09-15 | 2012-06-13 | 塩野義製薬株式会社 | Hivインテグラーゼ阻害活性を有するカルバモイルピリドン誘導体 |
WO2006030807A1 (ja) * | 2004-09-15 | 2006-03-23 | Shionogi & Co., Ltd. | Hivインテグラーゼ阻害活性を有するカルバモイルピリドン誘導体 |
US9512125B2 (en) | 2004-11-19 | 2016-12-06 | The Regents Of The University Of California | Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents |
US8129385B2 (en) | 2005-04-28 | 2012-03-06 | Shionogi & Co., Ltd. | Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness |
US8778943B2 (en) | 2005-04-28 | 2014-07-15 | Shionogi & Co., Ltd. | Substituted 10-hydroxy-9,11-dioxo-2,3,4a,5,9,11,13,13a-octahydro-1h-pyrido[1,2-α]pyrrolo[1′,2′:3,4]imidazo[1,2-d]pyrazine-8-carboxamides |
EP2527007A1 (en) | 2005-04-28 | 2012-11-28 | GlaxoSmithKline LLC | Polycyclic carbamoylpyridone derivative having hiv integrase inhibitory activity |
US8410103B2 (en) | 2005-04-28 | 2013-04-02 | Shionogi & Co., Ltd. | (3S,11aR)-N-[2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide useful as anti-HIV agent |
US11267823B2 (en) | 2005-04-28 | 2022-03-08 | Shionogi & Co., Ltd. | Substituted 1,2,3,3a,4,5,7,9,13,13a-decahydropyrido[1′,2′:4,5]pyrazino[1,2-a]pyrrolo[1,2-c]pyrimidines having HIV integrase inhibitory activity |
US10927129B2 (en) | 2005-04-28 | 2021-02-23 | Shinogi & Co., Ltd. | N-[(2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3] oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide having HIV integrase inhibitory activity |
EP3372281A1 (en) | 2005-04-28 | 2018-09-12 | VIIV Healthcare Company | Polycyclic carbamoylpyridone derivative having hiv integrase inhibitory activity |
EP3284520A1 (en) | 2005-04-28 | 2018-02-21 | VIIV Healthcare Company | Polycyclic carbamoylpyridone derivative having hiv integrase inhibitory activity |
EP3284519A1 (en) | 2005-04-28 | 2018-02-21 | VIIV Healthcare Company | Polycyclic carbamoylpyridone derivative having hiv integrase inhibitory activity |
US9273065B2 (en) | 2005-04-28 | 2016-03-01 | Shionogi & Co., Ltd. | Substituted pyrido[1',2':4,5]pyrazino[1,2-a]pyrimidines as HIV integrase inhibitors |
EP3187225A1 (en) | 2005-04-28 | 2017-07-05 | VIIV Healthcare Company | Polycyclic carbamoylpyridone derivative having hiv integrase inhibitory activity |
EP3187226A1 (en) | 2005-04-28 | 2017-07-05 | VIIV Healthcare Company | Polycyclic carbamoylpyridone derivative having hiv integrase inhibitory activity |
US9051337B2 (en) | 2005-04-28 | 2015-06-09 | Shionogi & Co., Ltd. | Substituted 10-hydroxy-9,11-dioxo-2,3,4a,5,9,11,13,13a-octahydro-1h-pyrido[1,2-a]pyrrolo[1′,2′:3,4]imidazo[1,2-d]pyrazine-8-carboxamides |
EP2465580A1 (en) | 2005-04-28 | 2012-06-20 | Glaxosmithkline LLC | Polycyclic carbamoylpyridone derivatives having hiv integrase inhibitory activity |
EP3045206A1 (en) | 2005-04-28 | 2016-07-20 | VIIV Healthcare Company | Polycyclic carbamoylpyridone derivative having hiv integrase inhibitory activity |
JP2006342115A (ja) * | 2005-06-10 | 2006-12-21 | Shionogi & Co Ltd | Hivインテグラーゼ阻害活性を有する多環性化合物 |
US9493467B2 (en) | 2006-04-04 | 2016-11-15 | The Regents Of The University Of California | PI3 kinase antagonists |
US7585868B2 (en) | 2006-04-04 | 2009-09-08 | The Regents Of The University Of California | Substituted pyrazolo[3,4-D]pyrimidines as kinase antagonists |
US8642604B2 (en) | 2006-04-04 | 2014-02-04 | The Regents Of The University Of California | Substituted pyrazolo[3,2-d]pyrimidines as anti-cancer agents |
US9359349B2 (en) | 2007-10-04 | 2016-06-07 | Intellikine Llc | Substituted quinazolines as kinase inhibitors |
US9216982B2 (en) | 2008-01-04 | 2015-12-22 | Intellikine Llc | Certain chemical entities, compositions and methods |
US9822131B2 (en) | 2008-01-04 | 2017-11-21 | Intellikine Llc | Certain chemical entities, compositions and methods |
US11433065B2 (en) | 2008-01-04 | 2022-09-06 | Intellikine Llc | Certain chemical entities, compositions and methods |
US8785456B2 (en) | 2008-01-04 | 2014-07-22 | Intellikine Llc | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
US8703777B2 (en) | 2008-01-04 | 2014-04-22 | Intellikine Llc | Certain chemical entities, compositions and methods |
US9655892B2 (en) | 2008-01-04 | 2017-05-23 | Intellikine Llc | Certain chemical entities, compositions and methods |
US8637542B2 (en) | 2008-03-14 | 2014-01-28 | Intellikine, Inc. | Kinase inhibitors and methods of use |
US8993580B2 (en) | 2008-03-14 | 2015-03-31 | Intellikine Llc | Benzothiazole kinase inhibitors and methods of use |
US9637492B2 (en) | 2008-03-14 | 2017-05-02 | Intellikine Llc | Benzothiazole kinase inhibitors and methods of use |
US9828378B2 (en) | 2008-07-08 | 2017-11-28 | Intellikine Llc | Kinase inhibitors and methods of use |
US9096611B2 (en) | 2008-07-08 | 2015-08-04 | Intellikine Llc | Kinase inhibitors and methods of use |
US9629843B2 (en) | 2008-07-08 | 2017-04-25 | The Regents Of The University Of California | MTOR modulators and uses thereof |
US9790228B2 (en) | 2008-09-26 | 2017-10-17 | Intellikine Llc | Heterocyclic kinase inhibitors |
US8703778B2 (en) | 2008-09-26 | 2014-04-22 | Intellikine Llc | Heterocyclic kinase inhibitors |
US9296742B2 (en) | 2008-09-26 | 2016-03-29 | Intellikine Llc | Heterocyclic kinase inhibitors |
US8697709B2 (en) | 2008-10-16 | 2014-04-15 | The Regents Of The University Of California | Fused ring heteroaryl kinase inhibitors |
US8476282B2 (en) | 2008-11-03 | 2013-07-02 | Intellikine Llc | Benzoxazole kinase inhibitors and methods of use |
US8476431B2 (en) | 2008-11-03 | 2013-07-02 | Itellikine LLC | Benzoxazole kinase inhibitors and methods of use |
US9315505B2 (en) | 2009-05-07 | 2016-04-19 | Intellikine Llc | Heterocyclic compounds and uses thereof |
US8785454B2 (en) | 2009-05-07 | 2014-07-22 | Intellikine Llc | Heterocyclic compounds and uses thereof |
US9206182B2 (en) | 2009-07-15 | 2015-12-08 | Intellikine Llc | Substituted isoquinolin-1(2H)-one compounds, compositions, and methods thereof |
US8569323B2 (en) | 2009-07-15 | 2013-10-29 | Intellikine, Llc | Substituted isoquinolin-1(2H)-one compounds, compositions, and methods thereof |
US9522146B2 (en) | 2009-07-15 | 2016-12-20 | Intellikine Llc | Substituted Isoquinolin-1(2H)-one compounds, compositions, and methods thereof |
US8980899B2 (en) | 2009-10-16 | 2015-03-17 | The Regents Of The University Of California | Methods of inhibiting Ire1 |
US9216995B2 (en) | 2010-04-12 | 2015-12-22 | Shionogi & Co., Ltd. | Pyridone derivative having integrase inhibitory activity |
US9738644B2 (en) | 2010-05-21 | 2017-08-22 | Infinity Pharmaceuticals, Inc. | Chemical compounds, compositions and methods for kinase modulation |
US8604032B2 (en) | 2010-05-21 | 2013-12-10 | Infinity Pharmaceuticals, Inc. | Chemical compounds, compositions and methods for kinase modulation |
US9181221B2 (en) | 2010-05-21 | 2015-11-10 | Infinity Pharmaceuticals, Inc. | Chemical compounds, compositions and methods for kinase modulation |
US9388183B2 (en) | 2010-11-10 | 2016-07-12 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US8901133B2 (en) | 2010-11-10 | 2014-12-02 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US9840505B2 (en) | 2011-01-10 | 2017-12-12 | Infinity Pharmaceuticals, Inc. | Solid forms of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1 (2H)-one and methods of use thereof |
USRE46621E1 (en) | 2011-01-10 | 2017-12-05 | Infinity Pharmaceuticals, Inc. | Processes for preparing isoquinolinones and solid forms of isoquinolinones |
US9290497B2 (en) | 2011-01-10 | 2016-03-22 | Infinity Pharmaceuticals, Inc. | Processes for preparing isoquinolinones and solid forms of isoquinolinones |
US10550122B2 (en) | 2011-01-10 | 2020-02-04 | Infinity Pharmaceuticals, Inc. | Solid forms of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one and methods of use thereof |
US11312718B2 (en) | 2011-01-10 | 2022-04-26 | Infinity Pharmaceuticals, Inc. | Formulations of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one |
US8809349B2 (en) | 2011-01-10 | 2014-08-19 | Infinity Pharmaceuticals, Inc. | Processes for preparing isoquinolinones and solid forms of isoquinolinones |
US9295673B2 (en) | 2011-02-23 | 2016-03-29 | Intellikine Llc | Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof |
US8969363B2 (en) | 2011-07-19 | 2015-03-03 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US9605003B2 (en) | 2011-07-19 | 2017-03-28 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US9718815B2 (en) | 2011-07-19 | 2017-08-01 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US9056877B2 (en) | 2011-07-19 | 2015-06-16 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US9546180B2 (en) | 2011-08-29 | 2017-01-17 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US8785470B2 (en) | 2011-08-29 | 2014-07-22 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US9115141B2 (en) | 2011-08-29 | 2015-08-25 | Infinity Pharmaceuticals, Inc. | Substituted isoquinolinones and methods of treatment thereof |
US9321772B2 (en) | 2011-09-02 | 2016-04-26 | The Regents Of The University Of California | Substituted pyrazolo[3,4-D]pyrimidines and uses thereof |
US9895373B2 (en) | 2011-09-02 | 2018-02-20 | The Regents Of The University Of California | Substituted pyrazolo[3,4-D]pyrimidines and uses thereof |
US9200009B2 (en) | 2011-10-12 | 2015-12-01 | Shionogi & Co., Ltd. | Polycyclic pyridone derivative having integrase inhibitory activity |
US8841314B2 (en) | 2011-11-11 | 2014-09-23 | Pfizer Inc. | 2-Thiopyrimidinones |
US8835449B2 (en) | 2011-11-11 | 2014-09-16 | Pfizer Inc. | 2-thiopyrimidinones |
US9873673B2 (en) | 2011-11-11 | 2018-01-23 | Pfizer Inc. | 2-thiopyrimidinones |
US9399626B2 (en) | 2011-11-11 | 2016-07-26 | Pfizer Inc. | 2-thiopyrimidinones |
US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US9255108B2 (en) | 2012-04-10 | 2016-02-09 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US8828998B2 (en) | 2012-06-25 | 2014-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
US9527847B2 (en) | 2012-06-25 | 2016-12-27 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
US10131668B2 (en) | 2012-09-26 | 2018-11-20 | The Regents Of The University Of California | Substituted imidazo[1,5-a]pYRAZINES for modulation of IRE1 |
US10822340B2 (en) | 2012-09-26 | 2020-11-03 | The Regents Of The University Of California | Substituted imidazolopyrazine compounds and methods of using same |
US11613544B2 (en) | 2012-09-26 | 2023-03-28 | The Regents Of The University Of California | Substituted imidazo[1,5-a]pyrazines for modulation of IRE1 |
US9481667B2 (en) | 2013-03-15 | 2016-11-01 | Infinity Pharmaceuticals, Inc. | Salts and solid forms of isoquinolinones and composition comprising and methods of using the same |
US9751888B2 (en) | 2013-10-04 | 2017-09-05 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US9828377B2 (en) | 2013-10-04 | 2017-11-28 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US9359365B2 (en) | 2013-10-04 | 2016-06-07 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US10329299B2 (en) | 2013-10-04 | 2019-06-25 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US10675286B2 (en) | 2014-03-19 | 2020-06-09 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US9775844B2 (en) | 2014-03-19 | 2017-10-03 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US11541059B2 (en) | 2014-03-19 | 2023-01-03 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US11944631B2 (en) | 2014-04-16 | 2024-04-02 | Infinity Pharmaceuticals, Inc. | Combination therapies |
US11110096B2 (en) | 2014-04-16 | 2021-09-07 | Infinity Pharmaceuticals, Inc. | Combination therapies |
JPWO2016021539A1 (ja) * | 2014-08-06 | 2017-04-27 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ピリミジン−1−オール化合物の製造方法及びその中間体 |
RU2681937C2 (ru) * | 2014-08-06 | 2019-03-14 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Способ получения пиримидин-1-олового соединения и его промежуточного соединения |
WO2016021539A1 (ja) * | 2014-08-06 | 2016-02-11 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ピリミジン-1-オール化合物の製造方法及びその中間体 |
US10065930B2 (en) | 2014-08-06 | 2018-09-04 | Eisai R&D Management Co., Ltd. | Method for producing pyrimidine-1-ol compound, and intermediate thereof |
EP3757105A2 (en) | 2014-08-22 | 2020-12-30 | Shionogi & Co., Ltd | Polycyclic pyridone derivative having integrase inhibitory activity |
US9708348B2 (en) | 2014-10-03 | 2017-07-18 | Infinity Pharmaceuticals, Inc. | Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof |
US10941162B2 (en) | 2014-10-03 | 2021-03-09 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US10253047B2 (en) | 2014-10-03 | 2019-04-09 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US9771332B2 (en) | 2015-05-05 | 2017-09-26 | Pfizer Inc. | 2-thiopyrimidinones |
US11247995B2 (en) | 2015-09-14 | 2022-02-15 | Infinity Pharmaceuticals, Inc. | Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same |
US11939333B2 (en) | 2015-09-14 | 2024-03-26 | Infinity Pharmaceuticals, Inc. | Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same |
US10160761B2 (en) | 2015-09-14 | 2018-12-25 | Infinity Pharmaceuticals, Inc. | Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same |
JP2019512485A (ja) * | 2016-03-08 | 2019-05-16 | ノバルティス アーゲー | オルトミクソウイルス感染の処置に有用な三環式化合物 |
US11453677B2 (en) | 2016-03-08 | 2022-09-27 | Novartis Ag | Tricyclic compounds useful to treat orthomyxovirus infections |
US10759806B2 (en) | 2016-03-17 | 2020-09-01 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors |
US10919914B2 (en) | 2016-06-08 | 2021-02-16 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US11147818B2 (en) | 2016-06-24 | 2021-10-19 | Infinity Pharmaceuticals, Inc. | Combination therapies |
US11098051B2 (en) | 2016-08-29 | 2021-08-24 | Novartis Ag | Fused tricyclic pyridazinone compounds useful to treat orthomyxovirus infections |
US11912715B2 (en) | 2016-08-29 | 2024-02-27 | Novartis Ag | Fused tricyclic pyridazinone compounds useful to treat orthomyxovirus infections |
CN106810458A (zh) * | 2016-12-31 | 2017-06-09 | 武汉工程大学 | 一种拆分dl‑2‑氨基丙醇制备l‑2‑氨基丙醇的方法 |
CN106810458B (zh) * | 2016-12-31 | 2019-05-03 | 武汉工程大学 | 一种拆分dl-2-氨基丙醇制备l-2-氨基丙醇的方法 |
WO2019054427A1 (ja) | 2017-09-14 | 2019-03-21 | 第一三共株式会社 | 環状構造を有する化合物 |
US11629149B2 (en) | 2018-02-28 | 2023-04-18 | Novartis Ag | 10-(di(phenyl)methyl)-4-hydroxy-8,9,9A,10-tetrahydro-7H-pyrrolo[1′,2′:4,5]pyrazino[1,2-b]pyridazine-3,5-dione derivatives and related compounds as inhibitors of the orthomyxovirus replication for treating influenza |
CN108658784A (zh) * | 2018-04-26 | 2018-10-16 | 联化科技股份有限公司 | (r)-1-(4-甲基苯基)乙胺的合成方法 |
WO2020083662A1 (en) | 2018-10-23 | 2020-04-30 | Basf Se | Tricyclic pesticidal compounds |
WO2021209265A1 (en) | 2020-04-14 | 2021-10-21 | Basf Se | Tricyclic pesticidal compounds |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2003016275A1 (en) | Antiviral agent | |
WO2002070486A1 (fr) | Composes d'heteroaryle azote exerçant un effet inhibiteur sur l'integrase du vih | |
HK1042656A1 (zh) | 間質性肺炎和肺纖維化癥的預防和治療藥物 | |
WO2008120759A1 (ja) | ウレア化合物およびその用途 | |
WO2003011851A3 (en) | Aromatic hydroxamic acid derivatives useful as hdac inhibitors | |
JO2311B1 (en) | Alkyl inhibitors Ariel phosphodiesterase-4 | |
WO1998028282A3 (en) | OXYGEN OR SULFUR CONTAINING 5-MEMBERED HETEROAROMATICS AS FACTOR Xa INHIBITORS | |
EP1371640A4 (en) | NEW A-LIPONIC ACID DERIVATIVE AND ITS USE | |
WO2003047564A1 (fr) | Dérivé ayant une activité d'inhibition de l'intégrase du vih | |
AP2000001900A0 (en) | Halogeneted amidino amino acid derivatives useful as nitric oxide synthase inhibitors. | |
EP1500655A4 (en) | NEW INHIBITOR OF METHIONINE AMINOPEPTIDASE | |
WO2002070491A1 (fr) | Derive a noyau heteroaromatique azote presentant une activite d'inhibiteur d'integrase du vih | |
EP1921062A3 (en) | Amino acid derivatives as HIV aspartyl protease inhibitors | |
MY117789A (en) | Pyrroloquinolones as antiviral agents | |
MXPA03009602A (es) | Analogos de nociceptina. | |
WO2003082881A3 (en) | Pyridoxal-5-phosphate derivatives as hiv integrase inhibitors | |
EP1671948A4 (en) | CINNAMOYL COMPOUND AND USE THEREOF | |
MXPA04003766A (es) | Derivados de 2-amino-4-heteroariletil tiazolina y su utilizacion como inhibidores de no sintasa inducible. | |
WO2001025239A3 (en) | Oxazinoquinolones useful for the treatment of viral infections | |
EP1671961A4 (en) | CINNAMOYL COMPOUND AND USE THEREOF | |
HK1066225A1 (en) | Processes for preparing pesticidal intermediates | |
EP1421946A4 (en) | Pharmaceutical Unit for Use in the Treatment of HIV Infection, Its Composition and Use | |
EP1393747A4 (en) | AGENT FOR PREVENTION / TREATMENT OF ALZHEIMER DISEASE | |
TW356471B (en) | Novel carbocyclic nucleoside agents useful as selective inhibitor of proinflammatory cytokines | |
WO2003076429A3 (en) | Azepane derivatives and their use as atk1 inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KR KZ LK LR LS LT LU LV MA MD MG MK MW MX MZ NO NZ OM PH PL PT RO SD SE SG SI SK SL TJ TM TN TR TT UA UG US UZ VC VN YU ZA ZM Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2003521202 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2452769 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2004/000646 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10485394 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020047002062 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002749384 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20028198697 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2002749384 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020107012655 Country of ref document: KR |